Affinage

ZMYND10

Zinc finger MYND domain-containing protein 10 · UniProt O75800

Length
440 aa
Mass
50.3 kDa
Annotated
2026-04-28
74 papers in source corpus 14 papers cited in narrative 14 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ZMYND10 is a cytoplasmic co-chaperone essential for the pre-assembly of inner and outer dynein arms (IDA/ODA) in motile cilia, with an additional role as a tumor suppressor in epithelial cancers. ZMYND10 confers substrate specificity to the FKBP8–HSP90 chaperone complex toward axonemal dynein heavy chain clients, stabilizes the ODA intermediate chain DNAI1, and physically interacts with dynein assembly factors LRRC6, DYX1C1, and C21ORF59 at cytoplasmic centriolar satellites (PMID:29916806, PMID:29601588, PMID:23891469). Loss-of-function mutations in ZMYND10 cause primary ciliary dyskinesia characterized by complete ciliary immotility, situs inversus, and male infertility, as demonstrated in human patients and validated across zebrafish, Xenopus, Drosophila, medaka, and mouse models (PMID:23891471, PMID:28823919). In cancer cells, ZMYND10 re-expression suppresses tumor growth by inhibiting JNK/ERK–cyclin D1 signaling and VEGF-mediated angiogenesis, and by upregulating miR-145-5p to target NEDD9 (PMID:22727408, PMID:25347745, PMID:31801619, PMID:16929489).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 2006 Medium

    ZMYND10 was first functionally validated as a bona fide tumor suppressor: inducible silencing of ZMYND10 in tumor-suppressive NPC clones restored tumorigenicity in nude mice, establishing that ZMYND10 expression is both necessary and sufficient for tumor suppression in this context.

    Evidence Tetracycline-regulated gene inactivation test with nude mouse xenografts of NPC cells

    PMID:16929489

    Open questions at the time
    • Molecular target or signaling pathway mediating tumor suppression not identified
    • Single cancer type tested
  2. 2012 Medium

    The tumor-suppressive mechanism was linked to specific signaling pathways: ZMYND10 re-expression arrested NPC cells in G1 by downregulating JNK activity and cyclin D1 promoter activity, and separately interacted with sMEK1 (PP4 regulatory subunit) to promote apoptosis, defining candidate effector pathways.

    Evidence Reporter assays for JNK/cyclin D1, Co-IP with domain mapping for sMEK1, flow cytometry in NPC cells

    PMID:22349239 PMID:22727408

    Open questions at the time
    • Whether JNK inhibition and sMEK1 interaction operate in the same or parallel pathways is unclear
    • No direct enzymatic mechanism linking ZMYND10 to phosphatase activity
  3. 2013 High

    ZMYND10 was identified as a ciliary disease gene: patient mutations, combined with loss-of-function in zebrafish, Xenopus, and Drosophila, established that ZMYND10 is required for assembly of both IDA and ODA onto motile cilia, and that it physically interacts with the dynein assembly factor LRRC6 at cytoplasmic centriolar satellites.

    Evidence Human PCD patient genetics, morpholino knockdown in zebrafish/Xenopus, Drosophila P-element silencing with EM ultrastructure, reciprocal Co-IP with domain mutagenesis, colocalization with SAS6/PCM1

    PMID:23891469 PMID:23891471

    Open questions at the time
    • Biochemical mechanism of ZMYND10 in dynein arm pre-assembly not resolved
    • Whether ZMYND10 acts catalytically or as a scaffold unknown
  4. 2014 Medium

    ZMYND10 tumor-suppressive activity was extended to include anti-angiogenic function: ZMYND10 overexpression suppressed VEGF isoforms and inhibited endothelial tube formation both in vitro and in vivo, revealing a non-ciliary effector axis.

    Evidence PCR array, VEGF ELISA, tube formation assay, matrigel plug angiogenesis assay in NPC models

    PMID:25347745

    Open questions at the time
    • Direct molecular mechanism connecting ZMYND10 to VEGF transcriptional regulation not identified
    • Whether anti-angiogenic and cell-cycle arrest functions are coupled is unknown
  5. 2017 Medium

    Domain analysis in medaka revealed that the C-terminal MYND zinc finger domain is important but not solely sufficient for ciliary function, as a truncation lacking the MYND domain retained partial activity, indicating an additional functional region.

    Evidence Morpholino knockdown and TALEN knockout in medaka with EM and rescue by truncation mutants

    PMID:28823919

    Open questions at the time
    • Identity of the second functional domain not determined
    • Structure–function relationship for human ZMYND10 not directly tested
  6. 2018 High

    The core biochemical mechanism was resolved: ZMYND10 acts as a co-chaperone that directs the FKBP8–HSP90 complex toward axonemal dynein heavy chain clients, stabilizes DNAI1 which in turn stabilizes DNAI2, and interacts with a network of cytoplasmic dynein pre-assembly factors (LRRC6, DYX1C1, C21ORF59). Pharmacological FKBP8 inhibition phenocopied ZMYND10 loss.

    Evidence Zmynd10 knockout mouse, quantitative proteomics, FKBP8 pharmacological inhibition, Co-IP, Western blot stability assays, EM

    PMID:29601588 PMID:29916806

    Open questions at the time
    • Structural basis for ZMYND10–FKBP8 interaction not determined
    • Whether ZMYND10 also functions in IDA-specific chaperone complexes not resolved
    • Stoichiometry and assembly order of the ZMYND10-containing pre-assembly complex unknown
  7. 2019 Medium

    A distinct tumor-suppressive mechanism was uncovered in breast cancer: ZMYND10 upregulates miR-145-5p, which directly targets the NEDD9 3′-UTR to suppress invasion and tumor growth, expanding the oncology-relevant effector repertoire beyond JNK/ERK signaling.

    Evidence Ectopic expression in breast cancer lines, luciferase 3′-UTR reporter, xenograft assay

    PMID:31801619

    Open questions at the time
    • Mechanism by which ZMYND10 induces miR-145-5p expression unknown
    • Relevance of miR-145-5p/NEDD9 axis to ciliated cell biology not addressed
  8. 2025 Medium

    ZMYND10 was found to transcriptionally activate the E2f4 promoter, driving the E2f4–Deup1 axis required for centriole amplification during multiciliogenesis, revealing a role upstream of centriole biogenesis distinct from its dynein chaperoning function.

    Evidence shRNA knockdown in mouse ependymal cells, luciferase E2f4 promoter assay, RT-qPCR, Western blot

    PMID:41413096

    Open questions at the time
    • Whether ZMYND10 binds the E2f4 promoter directly or via a cofactor is not resolved
    • Relationship between E2f4 transcriptional activation and dynein co-chaperone function unclear
    • Not yet replicated in other multiciliated cell types

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis for ZMYND10's interaction with FKBP8 and dynein heavy chains, whether its transcriptional regulatory activities (E2f4, miR-145-5p) require the MYND zinc finger domain, and how its ciliary and tumor-suppressive functions are mechanistically related or independent.
  • No crystal or cryo-EM structure of ZMYND10 or its complexes
  • Whether ciliary and tumor-suppressive functions share common interactors is untested
  • No reconstituted in vitro chaperone assay with purified components

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 2 GO:0044183 protein folding chaperone 1
Localization
GO:0005829 cytosol 2 GO:0005815 microtubule organizing center 1
Pathway
R-HSA-1852241 Organelle biogenesis and maintenance 4 R-HSA-162582 Signal Transduction 2
Partners
C21ORF59DNAI1DYX1C1FKBP8LRRC6SMEK1
Complex memberships
FKBP8-HSP90 co-chaperone complex

Evidence

Reading pass · 14 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 ZMYND10 protein physically interacts with LRRC6 via the LRRC6 CS domain and the ZMYND10 C-terminal domain; certain disease-causing mutations in either protein abrogate this interaction. Both proteins colocalize with centriole markers SAS6 and PCM1 in the cytoplasm. Co-immunoprecipitation, domain mapping with mutants, immunofluorescence colocalization with centriole markers SAS6/PCM1 American journal of human genetics High 23891469 23891471
2013 Loss of ZMYND10 function (mutations in PCD patients, knockdown in zebrafish and Xenopus, Drosophila P-element silencing) causes absence of both inner dynein arms (IDA) and outer dynein arms (ODA) from cilia/flagella, leading to complete ciliary immotility, laterality defects, and male sterility. ZMYND10 is localized primarily to the cytoplasm. Patient mutation analysis, zebrafish morpholino knockdown (ciliary paralysis, cystic kidneys, otolith defects), Xenopus knockdown, Drosophila P-element gene silencing (IDA/ODA loss by EM, proprioception deficits, sterility), immunofluorescence American journal of human genetics High 23891469 23891471
2018 ZMYND10 acts as a co-chaperone that confers specificity of the FKBP8-HSP90 chaperone complex toward axonemal dynein heavy chain clients. Loss of ZMYND10 perturbs chaperoning of axonemal dynein heavy chains and triggers broader degradation of dynein motor subunits. Pharmacological inhibition of FKBP8 phenocopies the dynein motor instability seen in ZMYND10-deficient airway cells. Human disease-causing ZMYND10 variants disrupt its ability to act as an FKBP8-HSP90 co-chaperone. Mouse knockout genetics, quantitative proteomics, pharmacological FKBP8 inhibition, imaging, co-chaperone functional assays with disease variants eLife High 29916806
2018 ZMYND10 interacts with ODA intermediate chain components and cytoplasmic pre-assembly factors including LRRC6, DYX1C1, and C21ORF59. ZMYND10 stabilizes DNAI1 (ODA intermediate chain 1), which in turn stabilizes DNAI2. Loss of ZMYND10 in Zmynd10-/- mice causes absence of IDA and ODA despite normal 9+2 axoneme structure and normal cilia number. Co-immunoprecipitation, Zmynd10-/- mouse knockout, Western blot stability assays with co-expression experiments, transmission electron microscopy PLoS genetics High 29601588
2017 In medaka fish, zmynd10 knockdown causes loss of outer dynein arms (ODA) and ciliary immotility; the C-terminal MYND-type zinc finger domain is important for function but an additional functional domain also exists, as a C-terminal truncation retaining no zf-MYND is still partially functional. Adult zmynd10 TALEN knockout mutants display sperm dysmotility, scoliosis, and progressive polycystic kidney. Morpholino knockdown, TALEN knockout in medaka, transmission electron microscopy (ODA loss), rescue experiments with truncation mutants Developmental biology Medium 28823919
2020 In Paramecium tetraurelia, RNAi depletion of ZMYND10 causes severe ciliary defects and abnormal localization of the intraflagellar transport protein IFT43 along cilia, indicating a role in regulating IFT in addition to dynein arm assembly. RNAi knockdown, immunofluorescence localization of IFT43 European journal of protistology Low 33279757
2020 CRISPR/Cas9 knockout of zmynd10 in zebrafish recapitulates scoliosis in viable adult fish, linking ZMYND10 function to spinal curvature consistent with ciliary dysmotility causing cerebrospinal fluid flow defects. CRISPR/Cas9 targeted knockout in zebrafish, morphological phenotype scoring in adults Frontiers in cell and developmental biology Medium 33251213
2019 ZMYND10 enhances expression of miR145-5p in breast cancer cells, which suppresses NEDD9 protein by targeting the 3'-UTR of NEDD9 mRNA. Ectopic ZMYND10 expression induces apoptosis and suppresses cell growth, migration, invasion, and xenograft tumor growth. Ectopic expression in breast cancer cell lines, luciferase 3'-UTR reporter assay, in vivo xenograft assay Clinical epigenetics Medium 31801619
2012 BLU/ZMYND10 directly interacts with sMEK1 (regulatory subunit of protein phosphatase 4) via its N-terminal domain binding to the C-terminal domain of sMEK1, and this interaction induces pro-apoptotic activity and increases sMEK1 expression. Co-immunoprecipitation, domain-mapping experiments, apoptosis assays Cellular signalling Medium 22349239
2012 Re-expression of BLU/ZMYND10 in nasopharyngeal carcinoma cells arrests cell cycle at G1 phase, downregulates JNK and cyclin D1 promoter activities, and inhibits c-Jun phosphorylation, inhibiting clonogenic growth. Adenoviral re-expression, flow cytometry cell cycle analysis, reporter gene assay for JNK/cyclin D1, immunoblotting for phospho-c-Jun BMC cancer Medium 22727408
2006 Re-expression of BLU/ZMYND10 in NPC cells suppresses tumor formation in nude mice in vivo, and doxycycline-mediated downregulation of ZMYND10 in tumor-suppressive clones restores tumor formation, providing functional evidence for ZMYND10 as a tumor suppressor. Tetracycline-regulated gene inactivation test (GIT), nude mouse xenograft assay International journal of cancer Medium 16929489
2014 BLU/ZMYND10 overexpression in NPC cells suppresses VEGF165, VEGF189, and TSP1 expression at RNA and protein levels, reduces secreted VEGF, inhibits cellular invasion, migration, and tube formation, and exerts anti-angiogenic activity in vivo in matrigel plug assays. Stable transfection, PCR array, VEGF ELISA, tube formation assay, matrigel plug in vivo angiogenesis assay, nude mouse xenograft Oncogene Medium 25347745
2025 Zmynd10 knockdown in mouse ependymal cells (mEPCs) reduces ciliary density and downregulates E2f4 and Deup1 expression; Zmynd10 activates the E2f4 promoter transcriptionally, driving the E2f4-Deup1 axis required for centriole amplification and multiciliogenesis. shRNA knockdown in mEPCs, RT-qPCR, Western blot, luciferase promoter assay for E2f4 Scientific reports Medium 41413096
2018 BLU/ZMYND10 inhibits ERK signaling by reducing ERK substrate phosphorylation, inhibiting Elk reporter activity, and blocking cyclin D1 (CCND1) promoter activity; HRAS V12G-activated ERK and cyclin D1/B1 promoter activities are antagonized by BLU, arresting cells in G1 and reducing G2/M population. Adenoviral re-expression in NPC cells and xenografts, phosphorylation assays, Elk reporter assay, CCND1/CCNB1 promoter reporter with co-transfection of RAS V12G, FACS cell cycle analysis International journal of clinical and experimental pathology Low 31938097

Source papers

Stage 0 corpus · 74 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer discovery 367 30257958
2018 Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer discovery 324 29657135
2019 First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer discovery 213 31575541
2013 ZMYND10 is mutated in primary ciliary dyskinesia and interacts with LRRC6. American journal of human genetics 153 23891469
2013 Mutations in ZMYND10, a gene essential for proper axonemal assembly of inner and outer dynein arms in humans and flies, cause primary ciliary dyskinesia. American journal of human genetics 130 23891471
2022 Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. Journal of medicinal chemistry 126 35838760
2004 The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 115 15122337
2004 Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 104 14743209
2003 Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene 82 12629521
2019 BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulmonary pharmacology & therapeutics 79 30902655
2004 Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer letters 63 15922865
2003 Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. International journal of cancer 54 12794757
2018 ZMYND10 functions in a chaperone relay during axonemal dynein assembly. eLife 48 29916806
2005 Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence. International journal of cancer 48 15540210
2019 Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British journal of haematology 44 31309543
2008 RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain pathology (Zurich, Switzerland) 44 18616639
2018 ZMYND10 stabilizes intermediate chain proteins in the cytoplasmic pre-assembly of dynein arms. PLoS genetics 42 29601588
2006 Functional studies of the chromosome 3p21.3 candidate tumor suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma. International journal of cancer 41 16929489
2017 A label-free nanostructured plasmonic biosensor based on Blu-ray discs with integrated microfluidics for sensitive biodetection. Biosensors & bioelectronics 37 28501746
2014 Quantification of rolling circle amplified DNA using magnetic nanobeads and a Blu-ray optical pick-up unit. Biosensors & bioelectronics 37 25453736
2006 Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecologic oncology 35 17097722
2018 Hacking CD/DVD/Blu-ray for Biosensing. ACS sensors 30 29978699
2008 Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer research 30 18751390
2006 Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer letters 28 15885884
2023 A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Investigational new drugs 26 36763233
2017 BLU-285, DCC-2618 Show Activity against GIST. Cancer discovery 22 28077435
2022 Blood-Coated Sensor for High-Throughput Ptychographic Cytometry on a Blu-ray Disc. ACS sensors 20 35393855
2019 ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer. Clinical epigenetics 19 31801619
1990 Lung tumorigenicity of benzene oxide, benzene dihydrodiols and benzene diolepoxides in the BLU:Ha newborn mouse assay. Carcinogenesis 19 2401039
2024 BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Therapeutic advances in medical oncology 18 39444426
2020 Coding Variants Coupled With Rapid Modeling in Zebrafish Implicate Dynein Genes, dnaaf1 and zmynd10, as Adolescent Idiopathic Scoliosis Candidate Genes. Frontiers in cell and developmental biology 18 33251213
2015 Blu-ray based optomagnetic aptasensor for detection of small molecules. Biosensors & bioelectronics 18 26342583
2017 Loss of zinc finger MYND-type containing 10 (zmynd10) affects cilia integrity and axonemal localization of dynein arms, resulting in ciliary dysmotility, polycystic kidney and scoliosis in medaka (Oryzias latipes). Developmental biology 17 28823919
2012 Tumor suppressor BLU enhances pro-apoptotic activity of sMEK1 through physical interaction. Cellular signalling 17 22349239
2012 Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle, c-Jun N-terminal kinase and the cyclin D1 promoter. BMC cancer 17 22727408
2025 Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors. Cancer research 15 39945650
2013 Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis. Biochemical and biophysical research communications 15 23628417
2024 An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. Science translational medicine 14 38809966
2016 ZMYND10--Mutation Analysis in Slavic Patients with Primary Ciliary Dyskinesia. PloS one 13 26824761
2010 Distinct epigenetic domains separated by a CTCF bound insulator between the tandem genes, BLU and RASSF1A. PloS one 13 20877461
2025 Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222. Cancer research 12 39945638
2016 Blu-ray Technology-Based Quantitative Assays for Cardiac Markers: From Disc Activation to Multiplex Detection. Analytical chemistry 12 27268387
2014 Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma. Oncogene 12 25347745
2019 Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 11 30802754
2017 Tumor suppressor BLU promotes TRAIL-induced apoptosis by downregulating NF-κB signaling in nasopharyngeal carcinoma. Oncotarget 8 28029652
2013 BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents. The international journal of biochemistry & cell biology 8 23579097
2022 BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro. Biochemical and biophysical research communications 7 35093636
2019 P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). International journal of pharmaceutics 7 31759109
2020 Primary ciliary dyskinesia relative protein ZMYND10 is involved in regulating ciliary function and intraflagellar transport in Paramecium tetraurelia. European journal of protistology 6 33279757
2019 Blu-Ray Discs as Universal Biochip Substrates: Lithography-Free Surface Activation and Assay Patterning. ACS applied materials & interfaces 6 31525871
2015 Inactivation of BLU is associated with methylation of Sp1-binding site of BLU promoter in gastric cancer. International journal of oncology 6 26043875
2010 High-resolution melting analysis of BLU methylation levels in gastric, colorectal, and pancreatic cancers. Cancer investigation 6 20394502
2022 Gold nanoparticle decorated blu-ray digital versatile disc as a highly reproducible surface-enhanced Raman scattering substrate for detection and analysis of rotavirus RNA in laboratory environment. Journal of biophotonics 5 36054627
2013 Photoattachment of thiolated DNA probes on SU-8 spin-coated Blu-ray disk surfaces for biosensing. Journal of materials chemistry. B 5 32261697
2012 Tumor suppressor gene BLU is frequently downregulated by promoter hypermethylation in myelodysplastic syndrome. Journal of cancer research and clinical oncology 5 22246278
2014 Position-addressable digital laser scanning point fluorescence microscopy with a Blu-ray disk pickup head. Biomedical optics express 4 24575338
2003 [Analysis of suppressive roles of BLU gene at 3p21.3 in nasopharyngeal carcinoma]. Ai zheng = Aizheng = Chinese journal of cancer 4 12600284
2025 Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945. NPJ precision oncology 3 40836025
2018 BLU-667 Targets RET-Altered Cancers. Cancer discovery 3 29657136
2018 Tumor suppressor BLU exerts growth inhibition by blocking ERK signaling and disrupting cell cycle progression through RAS pathway interference. International journal of clinical and experimental pathology 3 31938097
1995 Tissue distribution of DNA adducts in pre-weanling BLU:Ha mice treated with a tumorigenic dose of fluoranthene. Cancer letters 3 7757965
1992 Hybridization relatedness of Israeli and U.S. bluetongue (BLU) serotypes using cDNA probes from BLU virus strain 11-UC8. Archives of virology 3 1309643
2024 Sodium arsenite impairs sperm quality via downregulating the ZMYND15 and ZMYND10. Environmental toxicology 2 38798119
2013 Blu-ray disk lens as the objective of a miniaturized two-photon fluorescence microscope. Optics express 2 24514733
2026 CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. Nature communications 1 41571637
2007 The blu Blur: mutation of a vesicular glutamate transporter reduces the resolution of zebrafish vision. Neuron 1 17196524
2026 Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST. Journal of medicinal chemistry 0 41807293
2026 Benzo[a]pyrene lowers the sperm quality in male rats by downregulating the expression of ZMYND15 and ZMYND10. Reproductive toxicology (Elmsford, N.Y.) 0 41850444
2025 AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors. Journal of experimental & clinical cancer research : CR 0 40405293
2025 Molecular Insights into Outer Dynein Arm Defects in Primary Ciliary Dyskinesia: Involvement of ZMYND10 and GRP78. Cells 0 40558543
2025 The fourth-generation EGFR tyrosine kinase inhibitor BLU-945 resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to cytotoxic anticancer drugs. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 0 41120063
2025 Zmynd10 drives centriole biogenesis and multiciliogenesis through the transcriptional regulation of E2f4. Scientific reports 0 41413096
2022 Silencing of ciliary protein ZMYND10 affects amitotic macronucleus division in Paramecium tetraurelia. European journal of protistology 0 35065333
2003 [Hypermethylation status of blu gene in nasopharyngeal lymphoma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 0 12697125